NASDAQ:RUBY - Rubius Therapeutics Stock Price, Forecast & News

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Rubius Therapeutics Inc (NASDAQ:RUBY) released its quarterly earnings results on Thursday, November, 14th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.06. During the same period in the previous year, the business posted ($0.42) EPS. View Rubius Therapeutics' Earnings History.

Rubius Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Rubius Therapeutics.

4 brokers have issued 1-year price objectives for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $40.00. On average, they expect Rubius Therapeutics' stock price to reach $19.50 in the next year. This suggests a possible upside of 128.9% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Rubius Therapeutics.

Media coverage about RUBY stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Rubius Therapeutics earned a news impact score of 2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Rubius Therapeutics.

Some companies that are related to Rubius Therapeutics include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Alector (ALEC), Regenxbio (RGNX), Bill.com (RVMD), Cortexyme (CRTX), Coherus Biosciences (CHRS), SpringWorks Therapeutics (SWTX), I-Mab (BDTX), Beam Therapeutics (BEAM), Editas Medicine (EDIT), NanoString Technologies (NSTG), Orchard Therapeutics (ORTX), BAVARIAN NORDIC/S (BVNRY) and Twist Bioscience (TWST).

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Marinus Pharmaceuticals (MRNS), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Aclaris Therapeutics (ACRS) and Adverum Biotechnologies (ADVM).

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

Rubius Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (11.49%), Capital World Investors (6.49%), Baillie Gifford & Co. (5.33%), Nikko Asset Management Americas Inc. (1.80%), Sumitomo Mitsui Trust Holdings Inc. (1.80%) and Janus Henderson Group PLC (0.94%). Company insiders that own Rubius Therapeutics stock include Christopher L Carpenter, Francis M Cuss, Robert Langer and Torben Straight Nissen. View Institutional Ownership Trends for Rubius Therapeutics.

RUBY stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., ARK Investment Management LLC, Janus Henderson Group PLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Bank of America Corp DE, New York State Common Retirement Fund and Credit Suisse AG. Company insiders that have sold Rubius Therapeutics company stock in the last year include Christopher L Carpenter, Robert Langer and Torben Straight Nissen. View Insider Buying and Selling for Rubius Therapeutics.

RUBY stock was bought by a variety of institutional investors in the last quarter, including Capital World Investors, FMR LLC, Abbot Financial Management Inc., EcoR1 Capital LLC, Alpine Global Management LLC, State Street Corp, Trexquant Investment LP and UBS Group AG. View Insider Buying and Selling for Rubius Therapeutics.

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RUBY stock can currently be purchased for approximately $8.52.

Rubius Therapeutics has a market capitalization of $679.90 million. The company earns $-89,190,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis. Rubius Therapeutics employs 142 workers across the globe.View Additional Information About Rubius Therapeutics.

The official website for Rubius Therapeutics is http://www.rubiustx.com/.

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]